PURPOSE: To explore the molecular mechanisms by which the C-C chemokine receptor type 3 (CCR3) and chemokine (C-C motif) ligand 11 (CCL11) regulate choroidal endothelial cell (CEC) migration and the interactions with the vascular endothelial growth factor (VEGF) signaling pathway. METHODS: Human retinal sections from young and aged donor normal eyes were immunolabeled. By real-time PCR, CCR3 mRNA was measured in retinal pigmented epithelium (RPE)/choroids obtained from young and aged human donor eyes and in cultured CECs exposed to hydrogen peroxide. CCR3 ligand and CCL11- or VEGF-stimulated CEC migration was also measured in the presence of the CCR3 inhibitor or control using fluorescence microscopy. Activation of Rac1, phosphorylated Akt as a readout for phosphoinositol 3-kinase signaling, and VEGFR2 activation were measured in CECs incubated with CCL11, VEGF, or combined CCL11/VEGF. RESULTS: CCR3 was expressed to a greater level in older compared with that in younger human retinas or RPE/choroids. Ligand-activated CCR3 increased CEC migration, which was inhibited by the CCR3 inhibitor. Rac1 activity, p-Akt, and p-VEGFR2 were significantly increased in CECs incubated with CCL11. The CCR3 inhibitor prevented VEGF-induced CEC migration and Rac1 activation in CECs. Rac1 activity was additively increased in CECs treated with CCL11 and VEGF compared with that in cells with CCL11 or VEGF treatment alone. Ligand-activated CCR3 caused VEGFR2 phosphorylation and coimmunoprecipitation of VEGFR2 and CCR3. CONCLUSIONS: Activated CCR3 promotes CEC migration and Rac1 activation and causes an association with and activation of VEGFR2. Cross-talk between CCR3 and VEGF signaling exists and may be important in choroidal neovascularization in human age-related macular degeneration.
PURPOSE: To explore the molecular mechanisms by which the C-C chemokine receptor type 3 (CCR3) and chemokine (C-C motif) ligand 11 (CCL11) regulate choroidal endothelial cell (CEC) migration and the interactions with the vascular endothelial growth factor (VEGF) signaling pathway. METHODS:Human retinal sections from young and aged donor normal eyes were immunolabeled. By real-time PCR, CCR3 mRNA was measured in retinal pigmented epithelium (RPE)/choroids obtained from young and aged humandonor eyes and in cultured CECs exposed to hydrogen peroxide. CCR3 ligand and CCL11- or VEGF-stimulated CEC migration was also measured in the presence of the CCR3 inhibitor or control using fluorescence microscopy. Activation of Rac1, phosphorylated Akt as a readout for phosphoinositol 3-kinase signaling, and VEGFR2 activation were measured in CECs incubated with CCL11, VEGF, or combined CCL11/VEGF. RESULTS:CCR3 was expressed to a greater level in older compared with that in younger human retinas or RPE/choroids. Ligand-activated CCR3 increased CEC migration, which was inhibited by the CCR3 inhibitor. Rac1 activity, p-Akt, and p-VEGFR2 were significantly increased in CECs incubated with CCL11. The CCR3 inhibitor prevented VEGF-induced CEC migration and Rac1 activation in CECs. Rac1 activity was additively increased in CECs treated with CCL11 and VEGF compared with that in cells with CCL11 or VEGF treatment alone. Ligand-activated CCR3 caused VEGFR2 phosphorylation and coimmunoprecipitation of VEGFR2 and CCR3. CONCLUSIONS: Activated CCR3 promotes CEC migration and Rac1 activation and causes an association with and activation of VEGFR2. Cross-talk between CCR3 and VEGF signaling exists and may be important in choroidal neovascularization in human age-related macular degeneration.
Authors: Anne J Ridley; Martin A Schwartz; Keith Burridge; Richard A Firtel; Mark H Ginsberg; Gary Borisy; J Thomas Parsons; Alan Rick Horwitz Journal: Science Date: 2003-12-05 Impact factor: 47.728
Authors: John W Crabb; Masaru Miyagi; Xiaorong Gu; Karen Shadrach; Karen A West; Hirokazu Sakaguchi; Motohiro Kamei; Azeem Hasan; Lin Yan; Mary E Rayborn; Robert G Salomon; Joe G Hollyfield Journal: Proc Natl Acad Sci U S A Date: 2002-10-21 Impact factor: 11.205
Authors: W Smith; J Assink; R Klein; P Mitchell; C C Klaver; B E Klein; A Hofman; S Jensen; J J Wang; P T de Jong Journal: Ophthalmology Date: 2001-04 Impact factor: 12.079
Authors: N Soga; N Namba; S McAllister; L Cornelius; S L Teitelbaum; S F Dowdy; J Kawamura; K A Hruska Journal: Exp Cell Res Date: 2001-09-10 Impact factor: 3.905
Authors: Imran A Bhutto; Sahng Y Kim; D Scott McLeod; Carol Merges; Naomi Fukai; Bjorn R Olsen; Gerard A Lutty Journal: Invest Ophthalmol Vis Sci Date: 2004-05 Impact factor: 4.799
Authors: Chandrasekharam N Nagineni; Vijay K Kommineni; Nader Ganjbaksh; Krishnasai K Nagineni; John J Hooks; Barbara Detrick Journal: Aging Dis Date: 2015-11-17 Impact factor: 6.745
Authors: Nori Nagai; Meihua Ju; Kanako Izumi-Nagai; Scott J Robbie; James W Bainbridge; David C Gale; Esaie Pierre; Achim H P Krauss; Peter Adamson; David T Shima; Yin-Shan Ng Journal: Am J Pathol Date: 2015-07-16 Impact factor: 4.307